Industry: biopharmaceutical Region: India Transaction price: US$ 1 million Transaction method: equity investment
Project introduction:
A global biopharmaceutical company headquartered in India was established in 2000, focusing on the production of active pharmaceutical ingredients (API) and preparations through fermentation and semi-synthesis processes. The company has a number of internationally certified modern production bases, and its products cover many therapeutic fields such as immunosuppressant, anti-tumor and antibacterial, and its business network covers more than 70 countries around the world. The company has the full chain capability from research and development, process development to large-scale production, and has a strong industry position in fermentation technology and complex API production.
Products and services:
API (active pharmaceutical ingredient): Fermented or semi-synthetic products covering immunosuppressant, antitumor, antibacterial and antifungal fields. Concord has a world-leading complex API product portfolio.
Formulations: providing oral solid, liquid and suspension products in the field of nephrology and critical care, and some of them are sold to the United States and other international markets.
Contract Research & Manufacturing (CDMO/CRAMs): It covers the whole chain services from strain modification, medium optimization, process development and amplification, to finished dosage form development and commercial scale manufacturing.
Cooperation mode:
The enterprise is seeking technical cooperation in the field of fermented products. We hope to carry out joint research and development, technology transfer or other forms of cooperation with partners with advanced technologies or solutions to further optimize fermentation processes and promote product innovation.